Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Y L, Matory"'
Autor:
Y L, Matory
Publikováno v:
Current opinion in general surgery.
There have been several new developments in breast cancer research. Investigators are closer to identifying the breast cancer gene, which may aid in the diagnosis and treatment of the disease. The more established routine of screening mammography has
Publikováno v:
Surgery, gynecologyobstetrics. 177(4)
We reviewed our experience with 69 patients with carcinoma of the ampulla of Vater admitted to the Memorial Sloan-Kettering Cancer Center, New York, from October 1983 to October 1990. Of the 69 patients, 66 were explored and 55 underwent resection (8
Autor:
M T, Lotze, Y L, Matory, S E, Ettinghausen, A A, Rayner, S O, Sharrow, C A, Seipp, M C, Custer, S A, Rosenberg
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 135(4)
Purified recombinant human interleukin 2 (RIL 2) derived from E. coli containing the inserted gene encoding for IL 2 was administered to 20 patients with a variety of malignancies. Toxicity was dose related and included fever, chills, malaise, arthra
Autor:
M T, Lotze, Y L, Matory, A A, Rayner, S E, Ettinghausen, J T, Vetto, C A, Seipp, S A, Rosenberg
Publikováno v:
Cancer. 58(12)
Interleukin-2 (IL-2) is a 15,000 dalton glycoprotein produced naturally by human T-cells during an immune response. IL-2 has been demonstrated to have substantial activity alone or in combination with the adoptive transfer of lymphokine-activated kil
Publikováno v:
Surgery, gynecologyobstetrics. 161(6)
The Kasai I and Suruga I procedures are the most commonly reported surgical procedures used for the correction of biliary atresia. Clinical results are similar for these two procedures, but the Suruga I procedure is associated with a lower incidence
Publikováno v:
Journal of biological response modifiers. 4(4)
The recent availability of recombinant human interleukin-2 (RIL-2) has increased interest in the potential clinical use of this lymphokine. We have examined the biologic effects of intermittent bolus and continuous intravenous administration of RIL-2